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INTRODUCTION
The main purpose of the tumor marker
measurement is palindromic early detection, a
monitor of the supporting clinical course for the
effect of treatment judgment. In addition, prog-
nostic predictions, a diagnostic aid of the early
cancer and progress of the primary carcinoma
are done.
“The guide of the effect of treatment judg-
ment using a marker”was shown by a Japanese
breast cancer society squad study in 2001. It
evaluated that the change of the marker level
reflected condition for progress / the recurrent
breast cancer cases of the marker positive.
On the other hand, comparing high specific-
ity, sensitivity of prostatespecific antigen in the
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ABSTRACT
We investigated a prognosis in the pres-
ence or absence of preoperative marker abnor-
mality for 371 cases with primary breast cancer
that we experienced in our department this
time. 60 (16%) of 371 cases showed the abnor-
mality of the tumor marker and 25 (41.7%) of 60
patients had a recurrence. The positive rate of
the marker was 8.1% in CA 153, 6.7% in CEA,
4.1% in NCCST439, and each rate of recur-
rence was 56.7%, 48.0%, 33.3%. Rate of recur-
rence in the negative cases was 12.7%, 13.9,
15.0% respectively and recognized a significant
difference statistically (p <0.001) . Of 11 cases
(3.8%) shown CA 153 abnormal high level, 3
cases (27.2%) had recurrence when we exam-
ined in 03 metastases to lymph nodes accord-
ing to markers. 281 cases (96.2%) was normal
range in CA153. Only 15 cases (5%) had recur-
rence. It showed a significant difference statisti-
cally (p <0.05) . For the cases shown abnormal-
ity of the preoperative CA 153, careful serial
observations are necessary.
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prostatic carcinoma detection, superior marker
in breast cancer about the diagnosis of the early
cancer is absent.
A prognosis seems to be poor for cases
shown the abnormal high level of the marker
when we compare a prognosis in the abnormal
presence of the marker about the prognostic
prediction with the tumor marker in the pri-
mary breast cancer cases according to a clinical
stage.
We investigated a prognosis in the pres-
ence or absence of preoperative marker abnor-
mality for the primary breast cancer cases that
we experienced in our department this time.
OBJECTIVES
It is widely admitted as common practice
that the tumor marker of the breast cancer is
measured for postoperative palindromic early
detection, a judgment of the effect of treatment,
monitoring of the progress. Also, it is general to
measure tumor markers before initial treatment
for a primary breast cancer, but there are few
reports that reviewed the significance.
We studied whether we produced a differ-
ence as for the rate of recurrence by having ab-
errant high level or not of the tumor marker in
the patient with primary breast cancer.
MATERIALS AND METHODS
We intended for 371 patients with primary
breast cancer which we experienced in our de-
partment for from January, 2001 to November,
2006.
The average age of patients was 56 (2586
years old) and the average observation period
was 3.5 (1.06, 8 years) .
When distribute cases according to stage,
27cases (7%) was in stage0, 87 (23.5%) in stage
Ⅰ, 113 (30.5%) in stage Ⅱ A, 39 (10.6%) in stage
Ⅱ B, 22 (6%) in stage Ⅲ A, 50 (13.5%) in stage
Ⅲ B, 5 (1.3%) in stage Ⅲ C, 28 (7.6%) in stage
Ⅳ. Also, 223 cases (60.1%) don't have any
lymph node metastasis, 69 cases (18.6%) have 1
3 lymph node metastases, 32 cases (8.6%) have
49 lymph node metastases, and 47 cases (12.7%)
have over ten lymph node metastasis by me-
tastases to lymph nodes number distinction.
We measured tumor marker CA 153, CEA
(carcino embryonic antigen) , NCCST439 for
371 breast cancer cases before the preoperation
or chemoendocrinetherapy. The cutoff limit was
established at 30.0U/ml, 5.5 U/ml, 7 U/ml re-
spectively. We measured markers after an op-
eration and/or chemoendocrinetherapy every 3
6 months.
We investigated the rate of recurrence of
the breast cancer case shown aberrant high
level before treatment according to stage of dis-
ease and the metastases to lymph nodes num-
ber.
The statistics were assessed using Wald
method by Proportional Hazard Model.
RESULTS
After the diagnosis the average followup
time was 3.5 years (range16.8years) . CA153,
CEA, NCCST439 were assessed from 371
breast cancer patients before operation or
chemoendocrinetherapy.
60 (16%) of 371 patients with primary
breast cancer had the abnormality of the tumor
marker. 25 patients (41.7%) of those had recur-
rence.
On the other hand, of 311 (84%) marker
negative cases, 35 patients (11.3%) had a recur-
rence (Table1) . The positive rate of the mark-
ers were 8.1% in CA 153, 6.7% in CEA, 4.1% in
NCCST439. Also, each rate of recurrence was
56.7%, 48.0%, 33.3%. Rate of recurrence of the
negative cases were 12.7%, 13.9, 15.0% respec-
tively. It recognized a significant difference sta-
tistically (p <0.001) (Table2) .
We studied recurrence rate of marker posi-
tive cases and the negative cases according to
Stage. The results did not show a significant dif-
ference statistically (Table3) . Also, we exam-
ined recurrence rate of marker positive cases
and the negative cases in 0, 13, 49, over ten
lymph nodes metastasis according to the num-
ber of the metastases to lymph nodes equally.
As the results, it did not recognize a significant
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difference statistically (Table4) . However, rate
of recurrence tended to be high for a marker
positive case in 0 metastases to lymph nodes
and also 13 metastases.
As for 11 cases (3.8%) shown CA 153 ab-
normal high level, 3 patients (27.2%) of those
showed a recurrence when we examined in 03
metastases to lymph nodes according to a
marker (Table5) . On the other hand, of 281
cases (96.2%) shown CA 153 normal level, only
15 cases (5%) had recurrence. It showed a sig-
nificant difference statistically (p <0.05) .
Table １ Results of Tumor Marker（TM）analysis
Number of
cases
Number of recurrent cases
Total ３７１（１６．２％） ６０（１６．２％）
TM (+ve)
TM (ve)
６０（１６．２％）
３１１（８３．３％）
２５（４１．７％） 
P＜０．００１
３５（１１．３％） 
Table ２ Results of Each TM analysis
Tumor
marker
Number of
cases
Number of
TM(+ve)
Cases
Number of
reccurent
cases
Number of
TM(ve)
cases
Number of
recurrent
cases
Pvalue
CA１５３ ３７１ ３０（８．１） １７（５６．７） ３４１（９１．９） ４３（１２．７） P＜０．００１
CEA ３７１ ２５（６．７） １２（４８．０） ３４６（９３．３） ４８（１３．９） P＜０．００１
NCCST４３９ ３７１ ２４（４．１） ８（３３．３） ３４７（９５．９） ５２（１５．０） P＜０．００１
Table ３ Results of TM analysis in Stage
Stage
Number of
cases
Number of
TM(+ve)
cases
Number of
recurrent
cases
Number of
TM(ve)
cases
Number of
recurrent
cases
Pvalue
０ ２７ ０（０．０） ０（０．０） ２６（９６．３） ０（０．０） NS
Ⅰ ８７ ４（４．６） ０（０．０） ８３（９５．４） １（１．２） NS
ⅡＡ １１３ １２（１０．６） １（８．３） １０１（８９．４） ４（４．０） NS
ⅡＢ ３９ ５（１２．８） １（２０．０） ３４（８７．２） １（２．９） NS
ⅢＡ ２２ ３（１３．０） ０（０．０） １９（８２．６） ４（２１．１） NS
ⅢＢ ５０ １８（３６．０） ８（４４．４） ３２（６４．０） １２（３７．８） NS
ⅢＣ ５ ２（４０．０） １（５０．０） ３（６０．０） ２（６６．７） NS
Ⅳ ２８ １５（５３．６） １４（９３．３） １３（４６．４） １１（８４．６） NS
Table ４ Results of TM analysis in Lymph nodes status
Metastatic
lymph node
Number of
cases
Number of
TM(+ve)
cases
Number of
reccurent
cases
Number of
TM(ve)
cases
Number of
recurrent
cases
Pvalue
０ ２２３ １９（８．５） ２（１０．５） ２０４（９１．５） ６（２．９） NS
１～３ ６９ １０（１４．４） ２（２０．０） ５９（８５．５） ６（１０．２） NS
４～９ ３２ ８（２５．０） ５（６２．５） ２４（７５．０） １０（４１．７） NS
１０～ ４７ ２３（４８．９） １６（６９．６） ２４（５１．５） １５（６２．５） NS
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DISCUSSION
CA 153 (97%) , CEA (97%) , NCCST439
(68%) were routinely measured in clinical prac-
tice as the breast cancer tumor marker in Japan
according to the questionary survey of the Japa-
nese breast cancer society squad study in 2001.
Also, the measurement of CA 153 and CA
27.29 as breast cancer tumor marker were pro-
posed in the guideline of ASCO (American Soci-
ety of Clinical Oncology) 1）.
An examination for serum HER2 was evalu-
ated with trastuzumab (Herceptin) having been
marketed as a therapeutic drug of progress /
the recurrent breast cancer in 2001, and it was
with insurance adaptation in 2002. It is essential
postoperatively to evaluate the HER2 status
from breast cancer tissue and as for measuring
serum HER2 as a marker for the HER2 positive
case postoperatively, it seems with a use now
The measurement of prostatespecific anti-
gen is useful in early detection, a diagnosis of
the prostatic carcinoma. On the other hand,
specificity, sensitivity equivalent to it are absent
in the marker of breast cancer. There are many
institutions to measure in order of CA 153,
CEA, NCCST439, BCA225, TPA as a tumor
marker of the breast cancer. The sensitivity be-
fore the initial treatment has 520% in CA 153,
524% in CEA, 1633% in NCCST439, 12% in
BCA225 and 1235% in TPA. In our data, 60
(16%) of 371 patients with primary breast can-
cer had the abnormality of the tumor marker.
Each positive rate of tumor markers was 8.1%
in CA 153, 6.7% in CEA, 4.1% in NCCST439
and did not recognize a difference compared
other reports.
The sensitivity rate of that was 15% in
Stage Ⅰ, less than 510% in Stage Ⅱ. They
were low level. Also, it was 4.6% in Stage Ⅰ,
10.6% in Stage Ⅱ A, 12.8% in Stage Ⅱ B in our
data and did not recognize a difference com-
pared reported date. On the other hand, CA 15
3 were 5467%, CEA (2749%) , NCCST439
(4155%) , BCA225 (55%) and TPA (6282%) as
for the sensitivity in the recurrent breast can-
cer 2,3）.They were high level.
The main purpose of the current marker
measurement is palindromic early detection, a
monitor of the supporting clinical course for the
effect of treatment judgment. The marker
measurement as the monitoring of the patient
with recurrent breast cancer is performed in
Europe and America.
The positive rate of the tumor marker at
the time of the recurrence discovery varies by
recurrence part. In soft tissue, positive rate of
CA 153 and CEA was 26.7%, 18.1%. In bone,
CA 153 (50.0%) , CEA (30.2%) . In lung, CA 15
3 (36.6%) , CEA (31.0%) . In liver, CA 153
(71.4%) , CEA (59.5%) .
The positive rate of CA 153, CEA was
44.0%, 30.5% totally, that was 55.2% when either
CA 153 or CEA was abnormal high level4）.
There is a report that the change of the
marker reflects condition for progress, the re-
current breast cancer case of the marker posi-
tive in a Japanese breast cancer society squad
study in 2001. Furthermore, when tumor
marker value after treatment reduced 20% than
a tumor marker value at the time of the recur-
rence, an extension of the time toprogression is
obtained, and it was a factor independent of ef-
Table ５ Results of TM analysis in ０３Lymph nodes metastasis
Tumor
marker
Number of
cases
Number of
TM(+ve)
cases
Number of
recurrent
cases
Number of
TM(ve)
cases
Number of
recurrent
cases
Pvalue
CA１５３ ２９２ １１（３．８） ３（２７．２） ２８１（９６．２） １４（５．０） P＜０．０５
CEA ２９２ １１（３．８） １（９．０） ２８１（９６．２） １６（５．７） NS
NCCST４３９ ２９２ １２（４．１） １（８．３） ２８０（９５．９） １６（５．７） NS
AllTM ２９２ ２９（９．１） ４（１３．８） ２６３（９４．１） １３（４．９） NS
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fect of treatment5）.
There is the report that a prognosis is poor
for cases shown the abnormal high level of the
marker when we compare a prognosis in the
abnormal presence of the marker about the
prognostic prediction with the tumor marker in
the primary breast cancer cases according to a
clinical stage6）. It seems that undetectable po-
tential micrometastasis has been already pre-
sent in the cases that a marker shows aberrant
high level. Also, there is a report that various
markers are not secreted in breast cancer
which differentiation degree is low7）. The ex-
amination in our department showed a recur-
rence to 25 (42%) of 60 tumor marker abnor-
mality cases, 35 (11%) of 311 tumor marker nor-
mal cases. It showed a significant difference sta-
tistically (P<0.001) . The cases of the metastases
to lymph nodes number (03) showed connec-
tion in rate of recurrence and abnormal having
CA 153 or not.
It is important to measure tumor marker
for a primary breast cancer case.
When taking postoperative chemoendocri-
netherapy, it is usual that a recurrence risk clas-
sification of the St. Gallen consensus meeting
tends to make treatment preferences in refer-
ence to evaluating it.
It seems that we need attention in postop-
erative therapy in the cases with abnormal
marker.
When we suspect distant metastasis by the
abnormal elevation of the marker, we perform
an imaging study and find out an asymptomatic
recurrence lesion and then start palindromic
early treatment. It is supported by a Japanese
breast specialist4）. On contrary, that is not rec-
ommended as for the postoperative periodical
marker measurement because there are not
data that the time of discovering it controls the
prognosis of the patient a recurrence in Europe
and America1）. However, it is significant to
measure the markers of cases which tumor cells
in the primary breast cancer tissue after an op-
eration develop immunohistologically positive.
CONCLUSION
For the cases shown the abnormality of the
preoperative tumor marker, careful serial obser-
vations are necessary. When we admitted aber-
rant high level of the CA 153 in particular, rate
of recurrence is high in cases of 03 metastases
to lymph nodes. It is necessary to consider post-
operative treatment enough.
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